Michel Goldman, MD, PhD, was the first Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI), from 2009 to 2014. With a budget of 2 billions € provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he was responsible for 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer's dementia, autism, diabetes, immuno-inflammatory disorders, chronic pulmonary diseases and drug safety.
From 1990 to 2008, he was the Head of the Department of Immunology-Hematology-Transfusion at the Erasme Hospital of the Université Libre de Bruxelles (ULB), and from 2009 to 2014 he serves as the first Director of the Institute for Medical Immunology at ULB.
Currently, Michel Goldman is Professor of Immunology and Pharmacotherapy at ULB. He is a member of the Board of Directors of CQDM (Canadian consortium for precompetitive research), of the Board of the Tuberculosis Vaccine Initiative and of the Strategic and Scientific Advisory Board of GenomeQuebec. He is also a Senior Fellow of Fastercures, a center of the Milken Institute, and the Chairman of the Scientific Committee of Effimune S.A., a French biotechnology company.
Since November 2015, Michel Goldman will serve as the first Director of the Institute for Interdisciplinary Innovation in healthcare (I3h) newly created by ULB to foster research, education and outreach networks for the benefit of patients and other stakeholders.
Michel Goldman’s scientific achievements resulted in an ISI Highly Cited Scientist nomination in 2006 by the Thomson Institute for Scientific Information.
In 1992, Michel Goldman received the Medical Prize Lucien Steinberg (shared with Pr. Peter Piot) and in 2000 the Quinquiennal Prize of the Belgian National Fund for Scientific Research for Clinical Sciences. He held the Francqui Chair at the University of Namur in 1999, at the University of Liège in 2003, and the Spinoza chair at the University of Amsterdam, the Netherlands in 2001. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the University of Lille 2, France.